Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyCigna infliximab IV Prior Auth Policy Update | Ope…
    Ask Trek AI about this page
    CurrentCignaPolicy PSM005

    Infliximab Intravenous Products Preferred Specialty Management Policy

    Customize your policy alerts

    Sign up for Cigna Policy PSM005 alerts

    Get alerted when Policy PSM005 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Cigna's preferred specialty management program that governs prior authorization and preferred product sequencing for infliximab intravenous products for members covered by Cigna-administered health benefit plans.

    Policy Summary
    PayerCigna
    PolicyInfliximab Intravenous Products Preferred Specialty Management Policy
    Policy CodePolicy PSM005
    Change TypeRoutine review — no material changes
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 15, 2026
    Key ActionPatient must try at least one Preferred Product (Avsola or Inflectra) prior to approval of a Non-Preferred infliximab product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4products listed
    2preferred
    3non-preferred
    1exception groups

    Coverage Criteria for Infliximab Intravenous Products

    Policy Summary
    PayerCigna
    PolicyInfliximab Intravenous Products Preferred Specialty Management Policy
    Policy CodePolicy PSM005
    Change TypeRoutine review — no material changes
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 15, 2026
    Key ActionPatient must try at least one Preferred Product (Avsola or Inflectra) prior to approval of a Non-Preferred infliximab product.
    SourceLink
    On This Page
    Coverage Criteria for Infliximab Intravenous ProductsCoding and Billing CodesProvider Actions, Authorization & Billing RequirementsBackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred Specialty Management and Non-Preferred Product Exception

    Infliximab intravenous non-preferred products are considered medically necessary when the following non‑preferred product exception criteria are met. Any other exception is considered not medically necessary.

    Overall exception approval

    • A: Patient meets the standard Inflammatory Conditions - Infliximab Intravenous Products Prior Authorization Policy criteria

      See read-with prior authorization policy

    • B

      • i: Patient has tried ONE of Inflectra or Avsola

        Step therapy: try a Preferred Product prior to Non-Preferred

      • ii: Patient cannot continue to use the Preferred medication due to a formulation difference in the inactive ingredient(s) (e.g., differences in stabilizing agent, buffering agent, and/or surfactant) which, according to the prescriber, would result in an inability to tolerate or safely receive the Preferred product

        Prescriber must document the specific inactive ingredient formulation difference and clinical rationale why the Preferred product cannot be used

    Exclusion: Any exception not meeting the listed non-preferred product exception criteria is considered not medically necessary.

    Requests for non-preferred infliximab products that do not meet the exception criteria are considered not medically necessary.

    Infliximab intravenous non-preferred products are considered medically necessary only when the non-preferred product exception criteria are fully met. Per the policy, all patients (for Preferred and Non-Preferred products) must meet the standard Inflammatory Conditions - Infliximab Intravenous Products Prior Authorization Policy criteria, and patient must have tried at least one Preferred Product (Avsola or Inflectra) prior to approval of a Non-Preferred Product. Requests that do not meet the exception criteria are not medically necessary.

    Requests for Non-Preferred infliximab products that do not satisfy the listed non-preferred product exception criteria are considered not medically necessary. Providers must document that the patient meets the required prior authorization criteria and the exception criteria (including preferred product trial and prescriber justification related to formulation/inactive ingredient differences) for consideration of a Non-Preferred product approval.

    Coding and Billing Codes

    Coding guidancemixed
    not specifiedDocument does not list specific CPT/HCPCS/ICD-10 codes; providers must use the most appropriate codes as of the service date.
    Coding — N/A
    Coding listedDocument does not list specific CPT/HCPCS/ICD-10 codes; providers must use the most appropriate codes as of the service date.
    Denial riskClaims submitted without covered diagnosis and/or procedure codes under the applicable Coverage Policy will be denied as not covered.
    Billing instructionWhen billing, providers must use the most appropriate codes as of the effective date of the submission.

    Provider Actions, Authorization & Billing Requirements

    Prior Authorization

    Prior authorization required

    All infliximab intravenous products (Preferred and Non‑Preferred) require meeting the standard Inflammatory Conditions - Infliximab Intravenous Products Prior Authorization Policy criteria; approvals follow the duration specified in that prior authorization policy.

    Step Therapy

    Step: try a Preferred infliximab product first

    Before a Non‑Preferred infliximab product will be approved, the patient must have tried at least one Preferred Product (Avsola or Inflectra); Non‑Preferred requests are reviewed using the exception criteria.

    • Preferred Products: Avsola, Inflectra
    • Non‑Preferred requests evaluated against the Non‑Preferred Product Exception Criteria
    Billing Rule

    Use appropriate covered codes when billing

    When billing, providers must use the most appropriate codes as of the effective date of the submission; reimbursement is not allowed when billed for conditions or diagnoses not covered under this Coverage Policy.

    • Use covered diagnosis and/or procedure code(s) under the applicable Coverage Policy.
    • Claims lacking covered codes will be denied as not covered.
    Denial Risk

    Denial risk for missing covered codes

    Claims submitted for services that are not accompanied by covered diagnosis and/or procedure codes under the applicable Coverage Policy will be denied as not covered.

    Background

    Infliximab intravenous products (including brand Remicade and biosimilars such as Avsola, Inflectra, and Renflexis) are indicated for inflammatory conditions and share the same mechanism of action, route, dosage form, and strength. Biosimilars listed have demonstrated biosimilarity to Remicade but have not been designated as interchangeable; an authorized generic is produced using the same cell line as brand Remicade.

    Under this Preferred Specialty Management program, members are directed to try at least one Preferred Product (Avsola or Inflectra) before a Non-Preferred infliximab product will be approved, and Non-Preferred products may be approved only when the specified non-preferred product exception criteria are met.

    Definitions

    Biosimilar — definition and examples
    DefinitionBiosimilar: a product approved as biosimilar to Remicade (examples: Avsola, Inflectra, Renflexis) indicating no clinically meaningful differences in safety and effectiveness compared with Remicade.
    Same characteristicsApproved biosimilars share the same mechanism of action, route of administration, dosage form, and strength as Remicade.
    Inactive componentsMinor differences in clinically inactive components are allowed; such differences may affect formulation but do not imply interchangeability.
    Interchangeability statusAvsola, Inflectra, and Renflexis have demonstrated biosimilarity but have not demonstrated interchangeability at this time.
    Authorized generic — definition
    DefinitionAuthorized generic infliximab: produced using the same cell line as brand name Remicade and substitutable for brand Remicade for all indications.
    Source relationshipAuthorized generic is the same product lineage as Remicade (same cell line).
    SubstitutabilityFor all indications, infliximab authorized generic is substitutable for brand name Remicade.